Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone
Related news for (VINC)
- Vincerx Pharma, Inc. Announces Adjournment of Special Meeting – Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
- Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
- Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
- Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
- 24/7 Market News Snapshot 18 March, 2025 – Vincerx Pharma, Inc. Common Stock (NASDAQ:VINC)